Protara Therapeutics Inc（TARA）财务数据TARAProtara Therapeutics Inc

Evaluating the bottom line, Protara Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -45.80%, provide a clear picture of how effectively TARA converts its operational activities into shareholder value.

In the context of the broader market, TARA competes directly with industry leaders such as DERM and NGEN. With a market capitalization of $125.88M, it holds a significant position in the sector. When comparing efficiency, TARA's gross margin of N/A stands against DERM's 61.58% and NGEN's N/A. Such benchmarking helps identify whether Protara Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Protara has reported consistent net losses, with a net income of -$21.7 million in Q2 2026 and a negative EPS of -0.36. The company has a current ratio of 10.97, indicating it can cover its short-term liabilities, but its ongoing losses are concerning.